Difference between revisions of "Team:UiOslo Norway/Proof"
| Line 1: | Line 1: | ||
{{UiOslo_Norway}} | {{UiOslo_Norway}} | ||
| − | |||
<html> | <html> | ||
| Line 9: | Line 8: | ||
<div class="col-md-6"> | <div class="col-md-6"> | ||
<div id="proofofConcept"><h2 class="boxheader right"></h2></div> | <div id="proofofConcept"><h2 class="boxheader right"></h2></div> | ||
| − | |||
<img class="sidephotocolor" src="https://static.igem.org/mediawiki/2016/a/a8/T--UiOslo_Norway--3dev.jpg"/> | <img class="sidephotocolor" src="https://static.igem.org/mediawiki/2016/a/a8/T--UiOslo_Norway--3dev.jpg"/> | ||
</div> | </div> | ||
| Line 34: | Line 32: | ||
<p class="boxnotes rightext lastp"> | <p class="boxnotes rightext lastp"> | ||
Thus, we present a functioning chassis for a mobile diagnostic platform that easily, and within minutes can identify the presence of ESBL producing bacteria in urine samples, without ever having to expose any bacteria to antibiotics. | Thus, we present a functioning chassis for a mobile diagnostic platform that easily, and within minutes can identify the presence of ESBL producing bacteria in urine samples, without ever having to expose any bacteria to antibiotics. | ||
| − | |||
| − | |||
</p> | </p> | ||
</div> | </div> | ||
Revision as of 00:30, 20 October 2016
Proof Of Concept
As a proof of concept, we have successfully demonstrated all the central aspects of our projects with functioning set-ups.
Lab:
- Our colorimetric assay with nitrocefin is tested and validated, and our detection limits are within a clinically relevant range
- Using BBa_K1189031, a beta lactamase encoding biobrick designed by the Calgary team of 2013, we successfully showed that by using different combinations of inhibitors, we can pin-point the enzymatic class of the beta lactamase present in the samples.
- By purifying the BBa_K1189031 protein, testing it with nitrocefin and inhibitors and creating and validating our own biobricks for class A, B and C beta lactamases, we have demonstrated safe positive controls to test for these three classes of ESBLs.
Hardware:
Our 3D-printed case successfully interfaces urine samples to the phone, illuminates the sample,places and holds the samples on a optimal distance for camera focus.
Software:
We have successfully created an app with an user interface that accesses the camera, reads and analyze the color change induced by the cleavage of nitrocefin from a picture taken in our software. The app also includes an information page where users can read about guidelines regarding UTIs.
Thus, we present a functioning chassis for a mobile diagnostic platform that easily, and within minutes can identify the presence of ESBL producing bacteria in urine samples, without ever having to expose any bacteria to antibiotics.
Contact
